The increased incidence of emerging infections has caused a resurgence in the development
of animal models in order to study their pathophysiology and develop therapeutics against …

The inhalation of Francisella tularensis biovar A causes pneumonic tularemia associated
with high morbidity and mortality rates in humans. Exposure to F. tularensis usually occurs by …

Coronavirus disease 2019 (COVID-19) is an illness caused by a novel coronavirus, severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The disease was first identified as …

Pneumonic tularemia is a life-threatening disease caused by inhalation of the highly
infectious intracellular bacterium Francisella tularensis. The most serious form of the disease …

Background The pathogenesis of Francisella tularensis, the causative agent of tularemia,
has been primarily characterized in mice. However, the high degree of sensitivity of mice to …

Pneumonic tularemia caused by inhalation of the type A strains of Francisella tularensis is
associated with high morbidity and mortality in humans. The only vaccine known to protect …

Formulating vaccines into a dry form enhances its thermal stability. This is critical to prevent
administering damaged and ineffective vaccines, and to reduce its final cost. A number of …

Francisella tularensis, the causative agent of tularemia, is classified as Tier 1 Select Agent
with bioterrorism potential. The efficacy of the only available vaccine, LVS, is uncertain and it …

The inbred Fischer 344 rat is being evaluated for testing novel vaccines and therapeutics
against pneumonic tularemia. Although primary pneumonic tularemia in humans typically …

There are no defined correlates of protection for any intracellular pathogen, including the
bacterium Francisella tularensis, which causes tularemia. Evaluating vaccine efficacy against …